Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisamarie Ruffolo

Nurse Practitioner Orland Park, IL Nurse Practitioner

NPI 1801329743 CMS profile 10567804

10745 165Th St, Orland Park, IL 60467

Open in the dashboard

General payments

$12,566

431 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisamarie Ruffolo of Orland Park, IL is reported in the CMS Open Payments database as having received $12,566 across 431 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,865 92
2024 General $2,035 95
2023 General $1,671 92
2022 General $1,487 81
2021 General $1,509 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisamarie Ruffolo
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Lisamarie Ruffolo were reported at $5,865. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Lisamarie Ruffolo Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,509 $135 $40–$426 $132
2022 $1,487 $152 $48–$470 $149
2023 $1,671 $166 $54–$529 $160
2024 $2,035 $173 $55–$556 $164
2025 $5,865 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $6,026 120 payments
  2. ITI, Inc. $745 34 payments
  3. Corium, Inc. $678 31 payments
  4. Tris Pharma Inc $591 38 payments
  5. Neurocrine Biosciences, Inc. $514 24 payments
  6. Janssen Pharmaceuticals, Inc $506 22 payments
  7. Axsome Therapeutics, Inc. $446 17 payments
  8. Teva Pharmaceuticals USA, Inc. $430 15 payments
  9. Lundbeck LLC $354 18 payments
  10. Otsuka America Pharmaceutical, Inc. $327 14 payments
  11. Other $1,949 98 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,531 423 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,750 3 payments
  3. Education $158 2 payments
  4. Travel and Lodging $127 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $4,004 15 payments
  2. VRAYLAR Neuroscience $2,022 105 payments
  3. Azstarys $678 31 payments
  4. CAPLYTA $615 29 payments
  5. Dyanavel XR $544 35 payments
  6. INGREZZA $448 21 payments
  7. Auvelity $446 17 payments
  8. INVEGA SUSTENNA $335 14 payments
  9. FANAPT $324 10 payments
  10. REXULTI $253 12 payments
  11. Other $4,066 208 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,746

Median for Nurse Practitioner: 389

Drug cost

$231,207

Median for Nurse Practitioner: $21,885

Branded share of claims

22.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 50 $133,809
Rexulti Brexpiprazole Brand 16 $51,741
Trintellix Vortioxetine Hydrobromide Brand 13 $7,267
Paliperidone Er Paliperidone Brand 16 $5,694
Adderall Xr Dextroamphetamine/Amphetamine Brand 18 $4,488
Duloxetine Hcl Generic 105 $4,286
Bupropion Xl Bupropion Hcl Brand 127 $3,633
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 88 $2,390
Alprazolam Generic 228 $2,176
Quetiapine Fumarate Generic 61 $1,753

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $295
$295 — —
Azstarys
  • Corium, Inc. $293
$293 — —
VRAYLAR
  • AbbVie, Inc. $268
$268 50 —
Dyanavel XR
  • Tris Pharma Inc $173
$173 — —
REXULTI
  • Lundbeck LLC $109
  • Otsuka America Pharmaceutical, Inc. $50
$159 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

431 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record